Pioneering clinical study — approach supported by longer-term resultsPhase IINCT04165772
Primary analysis
Rectum
NEJM 2025: complete clinical response in 49/49 who completed treatment (complete clinical response ≠ cure)
Pioneering phase II; NEJM 2025 complete clinical response in 49/49 who completed treatment. Single-arm; AZUR-1 is a separate confirmatory trial.
Newly reported results · Registry checked: 2026-10-29
Applicable todayPhase IINCT05723562
Interim analysis · FDA accelerated approval — 19 October 2026 (US)
Rectum
~47% complete clinical response at 12 months (independent review) · US accelerated approval 19 Oct 2026
FDA accelerated approval 19 Oct 2026 (US). Single-arm; confirmatory follow-up to 2029/2030. Bridge to Rectum Landmark.
Practice-entering research · Registry checked: 2026-10-29
Still in researchPhase INCT04161755
Interim analysis
Pancreas
Pancreatic mRNA vaccine phase I (34 enrolled; 16 vaccinated). AACR 2026 longer follow-up — not standard care.
Early clinical research · Registry checked: 2026-11-03
Still in researchPhase I/IINCT05379985
Interim analysis
Pancreas · Multiple / solid tumors
RAS(ON) inhibitor phase I/II early activity; phase III (RASolute 302) is separate.
Early clinical research · Registry checked: 2026-10-29
Phase III · Positive results published · US-approvedPhase IIINCT06625320
Primary analysis · FDA approval — 26 August 2026 (US). Indication: metastatic pancreatic adenocarcinoma in adults after ≥1 prior systemic therapy or who are not candidates for multiagent systemic therapy. Label is not limited to RAS mutation. Türkiye license/SGK are separate.
Pancreas
Median overall survival 13.2 vs 6.7 mo (overall population) · US approval; Türkiye separate
Positive phase III overall survival/progression-free survival (NEJM); US-approved. Access in Türkiye separate. RAS G12 primary; overall population and label read separately.
Practice-entering research · Registry checked: 2026-10-29
Phase I/II · Recruiting · Research stagePhase I/IINCT06445062
Pancreas · Colon · Multiple / solid tumors
Phase I/II platform; still enrolling patients. Subprotocols A–G. RMC-6236 multiselective RAS(ON); RMC-9805 G12D-selective. Not merged with RASolute 302. Not a Landmark card.
Ongoing important trials · Registry checked: 2026-11-04
Phase III · Positive results published · US-approvedPhase IIINCT02912559
Primary analysis · FDA regular approval — 8 October 2026 (US). Atezolizumab (± subcutaneous hyaluronidase formulation) + fluoropyrimidine/oxaliplatin; adjuvant stage III dMMR colon. Türkiye license/SGK separate.
Colon
Primary card: Colon Landmark Atlas · Emerging is a bridge
Phase III disease-free survival benefit (NEJM); US-approved. overall survival not settled. Access in Türkiye separate. Primary card: Colon Landmark Atlas.
Practice-entering research · Registry checked: 2026-11-03
Becoming establishedPhase IINCT03026140
Primary analysis
Colon
Pathologic complete response ~68% (neoadjuvant immunotherapy, dMMR colon) — not non-operative standard
Published NICHE-2 cohort: high major response/pathologic complete response with neoadjuvant IO. Enrollment into that cohort is closed.
Newly reported results · Registry checked: 2026-11-01
Becoming establishedPhase IIINCT04949113
Primary analysis
Melanoma
Neoadjuvant ipi+nivo improved event-free survival in stage III melanoma (NEJM 2024).
Newly reported results · Registry checked: 2026-10-29
Becoming establishedPhase IINCT03897881
Interim analysis
Melanoma
Phase IIb: primary Lancet hazard ratio 0.561; ~3y update ~49% relative recurrence-free survival risk reduction — not a 49% cure rate.
Newly reported results · Registry checked: 2026-10-29
Phase III · Positive results published · US-approvedPhase IIINCT03504397
Final analysis · FDA approval — 18 October 2024 (US). Zolbetuximab-clzb (Vyloy) + fluoropyrimidine/platinum chemotherapy; CLDN18.2-positive, HER2-negative unresectable locally advanced or metastatic gastric/GEJ. Türkiye license/SGK separate.
Gastric / esophageal
Primary card: Gastric Landmark Atlas · Emerging is a bridge
Phase III progression-free survival/overall survival benefit (Lancet); US-approved. Access in Türkiye separate. Primary card: Gastric Landmark Atlas.
Practice-entering research · Registry checked: 2026-11-03
Becoming establishedPhase IIINCT03221426
Final analysis
Gastric / esophageal
Specimen cleared more often (13.4% vs 2.0%); the study did not meet its own success line for keeping disease away or prolonging life. Separate from MATTERHORN.
Newly reported results · Registry checked: 2026-10-29
Phase III · Positive results published · US-approvedPhase IIINCT04704934
Primary analysis · T-DXd is FDA-approved in the US for HER2-positive gastric/GEJ (initial approval based on DESTINY-Gastric01, 2021). DESTINY-Gastric04 strengthens comparative OS evidence; it is not itself a new licensing claim. Türkiye license/SGK separate.
Gastric / esophageal
Primary card: Gastric Landmark Atlas · Emerging is a bridge
2L T-DXd overall survival 14.7 vs 11.4 mo (hazard ratio 0.70). ILD critical. FDA label origin DG01; DG04 comparative evidence. Primary card: Gastric Landmark.
Practice-entering research · Registry checked: 2026-11-01
Phase III · Positive results published · US-approvedPhase IIINCT02989857
Final analysis · FDA approval — 25 August 2021 (US). Tibsovo (ivosidenib); previously treated, IDH1-mutant locally advanced or metastatic cholangiocarcinoma. Türkiye license/SGK separate.
Biliary tract
Primary card: Biliary tract cancer Landmark Atlas · Emerging is a bridge
Phase III progression-free survival benefit (Lancet Oncol); FDA 25 Aug 2021. overall survival complicated by crossover. Primary card: Biliary Landmark Atlas.
Practice-entering research · Registry checked: 2026-11-03
Becoming establishedPhase IIINCT03656536
Primary analysis
Biliary tract
ASCO 2026: primary progression-free survival met (8.3 vs 6.8 mo; hazard ratio 0.58). No overall-survival difference.
Newly reported results · Registry checked: 2026-11-03
Phase III · Positive results published · US-approvedPhase IIINCT04039607
Final analysis · FDA approval — 11 April 2025 (US). Opdivo + Yervoy; first-line unresectable/metastatic HCC. Türkiye licensing must be verified separately.
Liver (HCC)
1L nivo+ipi overall survival 23.7 vs 20.6 mo (hazard ratio 0.79); 4y follow-up hazard ratio 0.78. TRAE deaths 12 vs 3. FDA 11 Apr 2025. Child-Pugh A.
Practice-entering research · Registry checked: 2026-11-04
Becoming establishedPhase IIINCT04246177
Interim analysis
Liver (HCC)
TACE + lenvatinib + pembrolizumab; terminated on CT.gov — read interim results separately.
Newly reported results · Registry checked: 2026-10-29
Becoming establishedPhase II
Primary analysis
Colon
Stage II ctDNA-guided adjuvant; 2y recurrence-free survival non-inferiority. DYNAMIC-III (stage III) did not show recurrence-free survival gain from intensification.
Newly reported results · Registry checked: 2026-10-29
Still in researchPhase IINCT03287375
Primary analysis
Peritoneal metastasis · Colon
Completed example PIPAC listing — not ongoing. Randomized question: IMPACT (mitomycin PIPAC).
Early clinical research · Registry checked: 2026-11-03
Still in researchPhase INCT05737706
Pancreas · Multiple / solid tumors
KRAS G12D MRTX1133 phase I terminated early — no efficacy claim.
Early clinical research · Registry checked: 2026-10-29
Scientific discovery dossierExperimental discoveries
Pancreas · Multiple / solid tumors
Discovery dossier: RAS(ON) preclinical concept underpinning clinical programs — not a care standard.
Experimental models: Cell lines and animal models (clinical translation is on separate cards).
Translational distance: Human clinical benefit cannot be inferred here. Clinical: RMC-6236-001, RASolute 302, elironrasib/daraxonrasib.
Not a clinical trial or treatment option.
Becoming establishedPhase IINCT02008656
Primary analysis
Rectum
Watch-and-wait after TNT if complete clinical response (OPRA); disease-free survival ≠ organ preservation; induction vs consolidation TNT arms differ.
Newly reported results · Registry checked: 2026-10-29
Becoming establishedN/ANCT05384769
Interim analysis
Colon · Rectum
ctDNA observational/platform (GALAXY); phase N/A — results are cohort-specific.
Ongoing important trials · Registry checked: 2026-10-29
Scientific discovery dossierExperimental discoveriesDOI 10.1002/anie.202317578
Multiple / solid tumors
Discovery dossier: light-triggered endogenous Ca²⁺ storm. No human clinical efficacy evidence.
Experimental models: Tumor cell cultures; injectable HA-coated mesoporous silica nanomodulator; tumor regression after NIR irradiation reported in tumor-bearing mice.
Translational distance: Not a human clinical trial or approved therapy. Selectivity, systemic toxicity, and translation into surgical oncology practice are unproven.
Not a clinical trial or treatment option.
Scientific discovery dossierExperimental discoveriesDOI 10.1016/j.bbamcr.2014.02.012
Pancreas
Discovery dossier: STIM1/ORAI1 SOCE contributes to apoptotic resistance in PDAC cells — not a clinical test.
Experimental models: Pancreatic adenocarcinoma cell lines / in vitro SOCE measurements.
Translational distance: Not a validated clinical predictive test or approved drug target. Does not change surgical/adjuvant decisions.
Not a clinical trial or treatment option.
Scientific discovery dossierExperimental discoveriesDOI 10.21037/tcr-2024-2563
Multiple / solid tumors
Discovery dossier: SOCE_Score studied in neuroblastoma datasets — not a clinic-validated predictive test.
Experimental models: Multiple neuroblastoma RNA-seq datasets; claimed validation across cohorts; CMap drug-repurposing hypothesis.
Translational distance: Not a GI surgical oncology standard. Must not be presented as an approved predictive test. Needs medical review.
Not a clinical trial or treatment option.
Scientific discovery dossierExperimental discoveriesDOI 10.1002/emmm.201302989
Multiple / solid tumors
Discovery dossier: SOCE is critical for CD8+ antitumor immunity — not a human treatment protocol.
Experimental models: Conditional knockout mice; in vivo tumor-immunity experiments.
Translational distance: Generates immunotherapy-combination hypotheses; no clinical SOCE-inhibitor indication.
Not a clinical trial or treatment option.
Scientific discovery dossierExperimental discoveriesDOI 10.1016/j.biopha.2022.114074
Multiple / solid tumors
Discovery dossier (not one NCT): TRP–Ca²⁺–metastasis links are cancer-type specific; no claim that organ metastasis is ‘solved’.
Experimental models: Cell migration/invasion; xenograft/experimental metastasis mouse models; clinical cohort correlations (correlation ≠ causation).
Translational distance: A composite of multiple papers — not one clinical trial. Does not claim organ-specific metastasis mechanisms are fully solved.
Not a clinical trial or treatment option.
Still in researchPhase IIINCT05855200
Colon
Primary results not yet disclosed
Phase III; registry status still enrolling patients. Primary efficacy results not yet available.
Ongoing important trials · Registry checked: 2026-10-29
Still in researchPhase IIINCT06783491
Colon · Peritoneal metastasis
Phase III; still enrolling patients (CT.gov checked 2026-11-03). Neoadjuvant FOLFOX ± HIPEC — no results yet; do not confuse with PRODIGE 7.
Ongoing important trials · Registry checked: 2026-11-03
Still in researchPhase IIINCT07271355
Peritoneal metastasis · Colon
Phase III PIPAC; still enrolling patients (CT.gov checked 2026-11-03). Primary: overall survival. Separate from historical NCT03287375.
Ongoing important trials · Registry checked: 2026-11-03
Still in researchPhase II/IIINCT05174169
Colon
Phase II/III; still enrolling patients. US randomized ctDNA trial separate from DYNAMIC / CIRCULATE-Japan.
Ongoing important trials · Registry checked: 2026-10-29
Becoming establishedN/ANCT04264702
Primary analysis
Colon · Rectum
Observational; ctDNA MRD prognostic signal — separate from randomized CIRCULATE-US. Registry completed.
Newly reported results · Registry checked: 2026-11-03
Still in researchPhase IIINCT04340141
Pancreas
Phase III; enrollment closed — perioperative vs adjuvant mFOLFIRINOX results pending.
Awaiting results · Registry checked: 2026-10-29
Phase III · Positive results published · US-approvedPhase IIINCT04008030
Final analysis · FDA approval — 8 April 2025 (US). Nivolumab + ipilimumab; MSI-H/dMMR unresectable or metastatic colorectal cancer (≥12 years). Same action converted prior accelerated nivo monotherapy approval to regular (after fluoropyrimidine/oxaliplatin/irinotecan). Türkiye licensing must be verified separately.
Colon · Rectum
Primary card: Colon Landmark Atlas · Emerging is a bridge
1L nivo+ipi vs chemo: progression-free survival hazard ratio 0.21; final overall survival hazard ratio 0.37. All-lines nivo+ipi vs nivo: progression-free survival hazard ratio 0.62; overall survival hazard ratio 0.61. FDA 8 Apr 2025. Primary card: Colon Landmark.
Practice-entering research · Registry checked: 2026-11-04
Becoming establishedPhase IIINCT05152147
Primary analysis · US FDA approved two first-line zanidatamab-containing regimens for HER2-positive advanced gastric, GEJ, or esophageal adenocarcinoma on 25 August 2026. Eligibility differs by HER2 IHC/ISH status. Turkey licensing and reimbursement were not verified in this assessment.
Gastric / esophageal
NEJM May 2026: progression-free survival 12.4 vs 8.1 mo (zanidatamab±tislelizumab). Separate from DESTINY-Gastric04 / SPOTLIGHT.
Newly reported results · Registry checked: 2026-10-29
Still in researchPhase I/IINCT06128551
Pancreas · Multiple / solid tumors
Early-phase RAS(ON) combo; separate from RASolute 302 / RMC-6236-001.
Early clinical research · Registry checked: 2026-10-29
Still in researchPhase INCT04853017
Interim analysis
Pancreas · Multiple / solid tumors
Off-the-shelf amphiphile peptide+CpG vaccine; not part of the personalized mRNA neoantigen area.
Early clinical research · Registry checked: 2026-10-29
Still in researchPhase I/IINCT04166721
Gastric / esophageal
DKN-01 + atezolizumab; ACTIVE_NOT_RECRUITING (CT.gov checked 2026-11-03). Separate from SPOTLIGHT/KEYNOTE-585.
Early clinical research · Registry checked: 2026-11-03
Still in researchPhase IIINCT04969731
Pancreas
Phase III adjuvant cellular IO + gemcitabine; separate from PRODIGE-24 mFOLFIRINOX context.
Ongoing important trials · Registry checked: 2026-10-29
Still in researchPhase IIINCT05314998
Pancreas
Phase III biomarker-guided adjuvant; still enrolling patients (CT.gov checked 2026-11-03) — not yet a standard predictor.
Ongoing important trials · Registry checked: 2026-11-03
Still in researchPhase I/IINCT04599140
Colon · Rectum
Early phase; hypothesis to sensitize MSS RAS+ CRC to IO — separate from MSI IO.
Early clinical research · Registry checked: 2026-10-29
Research areaEmerging treatment technologiesPriority: very high
Melanoma · Pancreas · Multiple / solid tumors
Research area: personalized mRNA vaccines. KEYNOTE-942, V940 phase III, and pancreas vaccine cards are listed separately underneath.
Evidence level: Randomized phase IIb results in melanoma plus phase III confirmation trials; early clinical in pancreas.
Not a single trial · 3 linked records
Research areaEmerging treatment technologiesPriority: very high
Pancreas · Multiple / solid tumors
Research area: protein degradation. Setidegrasib (KRAS G12D) clinical card underneath; separate from classic inhibitor cards.
Evidence level: 2026 phase I clinical activity signal for KRAS G12D degrader setidegrasib (ASP3082) in NEJM; not standard care.
Not a single trial · 1 linked records
Research areaEmerging treatment technologiesPriority: very high
Gastric / esophageal · Biliary tract · Multiple / solid tumors
Research area: BsADCs. BL-B01D1 esophagus/biliary phase III cards underneath; zanidatamab is not an ADC.
Evidence level: Some molecules in phase III / regional programs; izalontamab brengitecan (BL-B01D1) as an example. Not all BsADCs are equivalent.
Not a single trial · 2 linked records
Research areaEmerging treatment technologiesPriority: high
Multiple / solid tumors
Research area: armored CAR-T. Early-phase ARMADA example underneath; do not conflate with hematologic CAR-T.
Evidence level: Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.
Not a single trial · 1 linked records
Still in researchPhase IIINCT05933577
Melanoma
Phase III confirmation; enrollment closed. Separate confirmatory trial of the KEYNOTE-942 phase IIb signal.
Awaiting results · Registry checked: 2026-10-29
Becoming establishedPhase INCT05382559
Interim analysis
Pancreas · Multiple / solid tumors
Phase I; NEJM 2026. ~24% objective response rate (share of tumors that shrink) in PDAC 600 mg cohort — early signal; not standard care.
Newly reported results · Registry checked: 2026-10-29
Becoming establishedPhase IIINCT06304974
Primary analysis · China NMPA approval — 17 July 2026 (China). US / EU / Türkiye assessed separately.
Gastric / esophageal
Phase III positive: overall survival 9.8 vs 7.2 mo (hazard ratio 0.64). China NMPA approval 17 July 2026.
Newly reported results · Registry checked: 2026-11-03
Still in researchPhase IIINCT07582315
Biliary tract
Phase III; still enrolling patients. Biliary BsADC — separate from ClarIDHy/FGFR context.
Ongoing important trials · Registry checked: 2026-10-29
Still in researchPhase INCT07783477
Multiple / solid tumors
Phase I armored CAR-T; still enrolling patients (CT.gov checked 2026-11-03). Solid tumor — not GI standard.
Early clinical research · Registry checked: 2026-11-03